ProfileGDS5678 / 1450416_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 30% 31% 19% 32% 32% 27% 29% 31% 31% 34% 31% 31% 43% 31% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.7072730
GSM967853U87-EV human glioblastoma xenograft - Control 22.6989631
GSM967854U87-EV human glioblastoma xenograft - Control 32.455819
GSM967855U87-EV human glioblastoma xenograft - Control 42.6772332
GSM967856U87-EV human glioblastoma xenograft - Control 52.6814232
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6979727
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.6968529
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.685731
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6869831
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.7515334
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6867931
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.68431
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.014143
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.6946131